Healthcare Global Enterprises Ltd

- Post-acquisition of Vizag, the company's debt will initially increase by Rs. 200 crores and later by another Rs. 150 crores after 18 months to complete an 85% acquisition. - The management plans to seek board approval at the appropriate time for a primary equity raise ("primary"), aimed at significantly reducing debt. - The exact size of the primary equity raise will be communicated when finalized. - The company intends to maintain its debt-to-equity ratio within internally accepted ranges, targeting a debt-to-EBITDA ratio of around 2.5x to 2.75x on a pre-Ind AS basis. - Currently, there are no mature inorganic acquisition opportunities under evaluation, but the company continues to assess strategic inorganic options. - CAPEX funding partly involves debt; Rs. 50 crores of the Rs. 80 crores CAPEX in Q1 was funded through debt, contributing to increased finance costs. - Overall, a primary equity raise is planned in the medium term to manage leverage following recent acquisitions.

- Current quarter CAPEX was about Rs. 80 crores. - CAPEX for the rest of the year is expected to remain in a similar range (around Rs. 80 crores per quarter). - Investments are focused on Brownfield facilities and new facilities like Whitefield and North Bangalore. - Additional ROU of Rs. 200 crores related to new facilities in Ahmedabad and North Bangalore added. - Post-acquisition of Vizag-based Mahatma Gandhi Hospital, no immediate additional equipment CAPEX planned, as the hospital is well-equipped (robotic unit, PET scan, linear accelerators). - A new linear accelerator is being added to the Vizag center as part of the CAPEX. - Company aims to optimize operational efficiencies and synergies across hospitals to drive growth and cost management.

- Q1 FY25 revenue at an all-time high of Rs. 526 crore, reflecting 17% growth YoY (adjusted for discontinued centers). - Established centers, excluding fertility business, grew 18% YoY with strong volume growth and improved realization. - Early Q2 performance strong, expected 14-15% growth QoQ, led by operational leverage. - Anticipated ongoing 13-15% revenue growth in existing hospitals for full year. - International business doubled compared to pre-COVID levels; focus on expanding markets in SAARC, Middle East, and Africa. - Acquisition of MG Hospital (Vizag) expected to boost consolidated revenue, expanding market share to 46% in region with 10-12% expected growth. - Emerging centers growing rapidly at 33% YoY; established centers growing at 14% YoY. - Improvements in Average Length of Stay (ALOS) and ARPOB (up 12% YoY) supporting volume and revenue expansion. - Expansion through Brownfield and new facilities, with CAPEX around Rs. 80 crores per quarter to support growth.

- Q1 FY25 showed strong performance with 17% revenue growth (adjusted) and 21% Adj. EBITDA growth. - Established centers grew revenue by 14% YoY; emerging centers grew 33% YoY in Q1. - MG Hospital acquisition in Vizag (85% stake) with 35% EBITDA margin added to future growth. - EBITDA margin expected near 20% for established businesses excluding acquisitions. - EBITDA margins and profits to improve as emerging centers mature and operating leverage increases. - PAT for Q1 was Rs. 12 crores, up 59% YoY; expected to improve gradually as subsidiaries turn profitable and benefit from better tax rates. - Early Q2 indications are positive, expecting ~15% YoY revenue growth and Rs. 100 crore+ EBITDA. - Debt to EBITDA targeted at 2.5x to 2.75x, with plans for equity raising to reduce debt and improve capital structure. - Revenue growth trajectory expected at 13-15% for established hospitals full-year basis.

- The transcript provided does not explicitly mention the current or expected order book or pending orders for HealthCare Global Enterprises Limited. - The discussion primarily focuses on financial performance, operational highlights, acquisitions (such as Vizag-based MG Hospital acquisition), CAPEX plans, debt management, and growth outlook. - There is no direct reference to specific order book details, contracts in hand, or pending orders within the provided pages. - For precise order book or pending orders information, please refer to the company's official financial disclosures or investor relations communications beyond this transcript.